Surgical treatment of hepatocellular carcinoma associated with the metabolic syndrome

British Journal of Surgery

Volumn 100, Issue 1, 2013, Pages 113-121

  Cauchy, F ^a   Zalinski, S ^a   Dokmak, S ^a   Fuks, D ^a   Farges, O ^a   Castera, L ^b   Paradis, V ^b   Belghiti, J ^a  

^a BEAUJON HOSPITAL   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AGED; ARTICLE; BIOPSY; CANCER GRADING; CANCER STAGING; FATTY LIVER; FEMALE; HUMAN; LENGTH OF STAY; LIVER CELL CARCINOMA; LIVER RESECTION; LIVER TUMOR; MALE; METABOLIC SYNDROME X; MIDDLE AGED; MORTALITY; PATHOLOGY; RETROSPECTIVE STUDY; SURVIVAL RATE; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; BIOPSY; CARCINOMA, HEPATOCELLULAR; FATTY LIVER; FEMALE; HEPATECTOMY; HUMANS; LENGTH OF STAY; LIVER NEOPLASMS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84870931049     PISSN: 00071323     EISSN: 13652168     Source Type: Journal    
DOI: 10.1002/bjs.8963     Document Type: Article

References (33)

1. Starley BQ, Calcagno CJ, Harrison SA,. Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection. Hepatology 2010; 51: 1820-1832.
2. Regimbeau JM, Colombat M, Mognol P, Durand F, Abdalla E, Degott C, et al., Obesity and diabetes as a risk factor for hepatocellular carcinoma. Liver Transpl 2004; 10 (Suppl 1): S69-S73.
3. Ertle J, Dechêne A, Sowa JP, Penndorf V, Herzer K, Kaiser G, et al., Non-alcoholic fatty liver disease progresses to hepatocellular carcinoma in the absence of apparent cirrhosis. Int J Cancer 2011; 128: 2436-2343.
4. Paradis V, Zalinski S, Chelbi E, Guedj N, Degos F, Vilgrain V, et al., Hepatocellular carcinomas in patients with metabolic syndrome often develop without significant liver fibrosis: a pathological analysis. Hepatology 2009; 49: 851-859.
5. Reddy SK, Steel JL, Chen HW, DeMateo DJ, Cardinal J, Behari J, et al., Outcomes of curative treatment for hepatocellular cancer in nonalcoholic steatohepatitis versus hepatitis C and alcoholic liver disease. Hepatology 2012; 55: 1809-1819.
6. Wakai T, Shirai Y, Sakata J, Korita PV, Ajioka Y, Hatakeyama K,. Surgical outcomes for hepatocellular carcinoma in nonalcoholic fatty liver disease. J Gastrointest Surg 2011; 15: 1450-1458.
7. Jonas S, Bechstein WO, Steinmuller T, Herrmann M, Radke C, Berg T, et al., Vascular invasion and histopathologic grading determine outcome after liver transplantation for hepatocellular carcinoma in cirrhosis. Hepatology 2001; 33: 1080-1086.
8. Cha C, Fong Y, Jarnagin WR, Blumgart LH, DeMatteo RP,. Predictors and patterns of recurrence after resection of hepatocellular carcinoma. J Am Coll Surg 2003; 197: 753-758.
9. Bamgbade OA, Rutter TW, Nafiu OO, Dorje P,. Postoperative complications in obese and nonobese patients. World J Surg 2007; 31: 556-560.
10. Belghiti J, Hiramatsu K, Benoist S, Massault P, Sauvanet A, Farges O,. Seven hundred forty-seven hepatectomies in the 1990s: an update to evaluate the actual risk of liver resection. J Am Coll Surg 2000; 191: 38-46.
11. Thuluvath PJ,. Morbid obesity with one or more other serious comorbidities should be a contraindication for liver transplantation. Liver Transpl 2007; 13: 1627-1629.
12. Eckel RH, Alberti KG, Grundy SM, Zimmet PZ,. The metabolic syndrome. Lancet 2010; 375: 181-183.
13. Ogata S, Belghiti J, Farges O, Varma D, Sibert A, Vilgrain V,. Sequential arterial and portal vein embolizations before right hepatectomy in patients with cirrhosis and hepatocellular carcinoma. Br J Surg 2006; 93: 1091-1098.
14. Dindo D, Demartines N, Clavien PA,. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 2004; 240: 205-213.
15. Balzan S, Belghiti J, Farges O, Ogata S, Sauvanet A, Delefosse D, et al., The '50-50 criteria' on postoperative day 5: an accurate predictor of liver failure and death after hepatectomy. Ann Surg 2005; 242: 824-848.
16. Ishizawa T, Hasegawa K, Kokudo N, Sano K, Imamura H, Beck Y, et al., Risk factors and management of ascites after liver resection to treat hepatocellular carcinoma. Arch Surg 2009; 144: 46-51.
17. Koch M, Garden OJ, Padbury R, Rahbari NN, Adam R, Capussotti L, et al., Bile leakage after hepatobiliary and pancreatic surgery: a definition and grading of severity by the International Study Group of Liver Surgery. Surgery 2011; 149: 680-688.
18. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings O, et al.,; Nonalcoholic Steatohepatitis Clinical Research Network. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005; 41: 1313-1321.
19. Brunt EM, Kleiner DE, Wilson LA, Belt P, Neuschwander-Tetri BA,; NASH Clinical Research Network (CRN). Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings. Hepatology 2011; 53: 810-820.
20. Welzel TM, Graubard BI, Zeuzem S, El-Serag HB, Davila JA, McGlynn KA,. Metabolic syndrome increases the risk of primary liver cancer in the United States: a study in the SEER-Medicare database. Hepatology 2011; 54: 463-471.
21. Saxena NK, Fu PP, Nagalingam A, Wang J, Handy J, Cohen C, et al., Adiponectin modulates C-jun N-terminal kinase and mammalian target of rapamycin and inhibits hepatocellular carcinoma. Gastroenterology 2010; 139: 1762-1773.
22. Yuen MF, Cheng CC, Lauder IJ, Lam SK, Ooi CG, Lai CL, et al., Early detection of hepatocellular carcinoma increases the chance of treatment: Hong Kong experience. Hepatology 2000; 31: 330-335.
23. Kamiyama T, Nakanishi K, Yokoo H, Kamachi H, Tahara M, Yamashita K, et al., Perioperative management of hepatic resection toward zero mortality and morbidity: analysis of 793 consecutive cases in a single institution. J Am Coll Surg 2010; 211: 443-449.
24. Balzan S, Nagarajan G, Farges O, Galleano CZ, Dokmak S, Paugam C, et al., Safety of liver resection in obese and overweight patients. World J Surg 2010; 34: 2960-2968.
25. Wong VW, Wong GL, Yip GW, Lo AO, Limquiaco J, Chu WC, et al., Coronary artery disease and cardiovascular outcomes in patients with non-alcoholic fatty liver disease. Gut 2011; 60: 1721-1727.
26. Vauthey JN, Pawlik TM, Ribero D, Wu TT, Zorzi D, Hoff PM, et al., Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol 2006; 24: 2065-2072.
27. Veteläinen R, van Vliet A, Gouma DJ, van Gulik TM,. Steatosis as a risk factor in liver surgery. Ann Surg 2007; 245: 20-30.
28. McCormack L, Petrowsky H, Jochum W, Furrer K, Clavien PA,. Hepatic steatosis is a risk factor for postoperative complications after major hepatectomy: a matched case-control study. Ann Surg 2007; 245: 923-930.
29. de Meijer VE, Kalish BT, Puder M, Ijzermans JN,. Systematic review and meta-analysis of steatosis as a risk factor in major hepatic resection. Br J Surg 2010; 97: 1331-1339.
30. Raptis DA, Fischer MA, Graf R, Nanz D, Weber A, Moritz W, et al., MRI: the new reference standard in quantifying hepatic steatosis? Gut 2012; 61: 117-127.
31. Agrawal S, Belghiti J,. Oncologic resection for malignant tumors of the liver. Ann Surg 2011; 253: 656-665.
32. Petrowsky H, McCormack L, Trujillo M, Selzner M, Jochum W, Clavien PA, et al., A prospective, randomized, controlled trial comparing intermittent portal triad clamping versus ischemic preconditioning with continuous clamping for major liver resection. Ann Surg 2006; 244: 921-928.
33. Mergental H, Adam R, Ericzon BG, Kalicinski P, Mühlbacher F, Höckerstedt K, et al., Liver transplantation for unresectable hepatocellular carcinoma in normal livers. J Hepatol 2012; 57: 297-305.